Long Term Study of Canakinumab (ACZ885) in Patients With Gout
Status:
Completed
Trial end date:
2010-08-04
Target enrollment:
Participant gender:
Summary
This 24-week open-label extension study is designed to provide additional long-term safety
data up to a total of 1-year for patients rolling over from the core study, and to collect
further efficacy and tolerability data for all the patients, irrespective whether they have
an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885)
in this extension study.